Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hodgkin Disease | 37 | 2023 | 1415 | 6.830 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 31 | 2023 | 1378 | 2.980 |
Why?
|
Lymphoma, Non-Hodgkin | 25 | 2021 | 1381 | 2.550 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 63 | 2023 | 11524 | 2.490 |
Why?
|
Burkitt Lymphoma | 6 | 2021 | 327 | 1.670 |
Why?
|
Lymphoma, Mantle-Cell | 11 | 2020 | 233 | 1.380 |
Why?
|
Stem Cell Transplantation | 18 | 2023 | 1620 | 1.340 |
Why?
|
Salvage Therapy | 9 | 2020 | 1275 | 1.240 |
Why?
|
Lymphoma, B-Cell | 9 | 2021 | 931 | 1.220 |
Why?
|
Transplantation, Autologous | 20 | 2023 | 2124 | 1.170 |
Why?
|
Doxorubicin | 27 | 2023 | 2234 | 1.060 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 19 | 2014 | 693 | 1.050 |
Why?
|
Lymphoma, Follicular | 8 | 2023 | 435 | 1.030 |
Why?
|
Positron-Emission Tomography | 21 | 2022 | 6234 | 1.000 |
Why?
|
Vincristine | 20 | 2022 | 1039 | 0.950 |
Why?
|
Cyclophosphamide | 27 | 2024 | 2242 | 0.910 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2024 | 1596 | 0.910 |
Why?
|
Herpesvirus 4, Human | 5 | 2021 | 1041 | 0.910 |
Why?
|
Lymphoma | 10 | 2023 | 1877 | 0.830 |
Why?
|
Vinblastine | 11 | 2023 | 502 | 0.820 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2021 | 570 | 0.810 |
Why?
|
Dacarbazine | 10 | 2023 | 566 | 0.720 |
Why?
|
Hematopoietic Stem Cell Transplantation | 17 | 2023 | 5442 | 0.710 |
Why?
|
Mediastinal Neoplasms | 6 | 2018 | 423 | 0.700 |
Why?
|
Education, Graduate | 1 | 2019 | 81 | 0.650 |
Why?
|
Lymphoma, T-Cell | 2 | 2014 | 299 | 0.630 |
Why?
|
Prednisone | 15 | 2022 | 1574 | 0.620 |
Why?
|
Disease-Free Survival | 31 | 2023 | 6895 | 0.600 |
Why?
|
Music Therapy | 3 | 2023 | 102 | 0.590 |
Why?
|
Etoposide | 13 | 2020 | 641 | 0.570 |
Why?
|
Lymphoproliferative Disorders | 3 | 2010 | 523 | 0.560 |
Why?
|
Immune Evasion | 1 | 2019 | 360 | 0.550 |
Why?
|
Proto-Oncogene Proteins c-myc | 5 | 2018 | 987 | 0.530 |
Why?
|
Fellowships and Scholarships | 3 | 2022 | 1076 | 0.510 |
Why?
|
Immunoconjugates | 3 | 2018 | 901 | 0.490 |
Why?
|
Fluorodeoxyglucose F18 | 9 | 2016 | 2016 | 0.490 |
Why?
|
Bleomycin | 8 | 2023 | 512 | 0.490 |
Why?
|
Recurrence | 19 | 2023 | 8340 | 0.480 |
Why?
|
Lymph Nodes | 3 | 2023 | 3474 | 0.460 |
Why?
|
Hematology | 3 | 2022 | 221 | 0.460 |
Why?
|
Radiopharmaceuticals | 7 | 2017 | 2645 | 0.450 |
Why?
|
Transplantation Conditioning | 9 | 2023 | 1598 | 0.450 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 3 | 2014 | 169 | 0.450 |
Why?
|
Viral Matrix Proteins | 1 | 2014 | 186 | 0.440 |
Why?
|
Career Choice | 1 | 2019 | 744 | 0.440 |
Why?
|
Lymphoma, T-Cell, Peripheral | 3 | 2023 | 134 | 0.430 |
Why?
|
Neoplasm Staging | 24 | 2023 | 11031 | 0.420 |
Why?
|
Humans | 155 | 2024 | 744343 | 0.420 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2012 | 119 | 0.410 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2014 | 286 | 0.410 |
Why?
|
Antibodies | 1 | 2019 | 2460 | 0.390 |
Why?
|
Vidarabine | 2 | 2024 | 345 | 0.370 |
Why?
|
Antineoplastic Agents | 21 | 2023 | 13695 | 0.360 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 180 | 0.340 |
Why?
|
Prognosis | 25 | 2023 | 29063 | 0.340 |
Why?
|
Adult | 74 | 2023 | 214055 | 0.330 |
Why?
|
Cytarabine | 8 | 2020 | 692 | 0.330 |
Why?
|
Treatment Outcome | 40 | 2024 | 63114 | 0.320 |
Why?
|
Referral and Consultation | 2 | 2014 | 3528 | 0.320 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2023 | 9239 | 0.320 |
Why?
|
Antibodies, Monoclonal | 8 | 2023 | 9274 | 0.310 |
Why?
|
Male | 86 | 2023 | 350118 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2022 | 1434 | 0.300 |
Why?
|
Female | 85 | 2023 | 380194 | 0.300 |
Why?
|
Medication Adherence | 1 | 2018 | 2063 | 0.290 |
Why?
|
Heart Neoplasms | 1 | 2010 | 374 | 0.280 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2014 | 1821 | 0.280 |
Why?
|
Middle Aged | 72 | 2023 | 213383 | 0.280 |
Why?
|
Medical Oncology | 4 | 2019 | 2265 | 0.280 |
Why?
|
Immunotherapy, Adoptive | 2 | 2019 | 1270 | 0.280 |
Why?
|
Protein Kinase C | 2 | 2008 | 1227 | 0.280 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1660 | 0.280 |
Why?
|
Protein Kinase Inhibitors | 7 | 2019 | 5535 | 0.270 |
Why?
|
Anthracyclines | 2 | 2023 | 288 | 0.270 |
Why?
|
Cancer Care Facilities | 1 | 2008 | 402 | 0.270 |
Why?
|
Tomography, X-Ray Computed | 14 | 2023 | 20129 | 0.260 |
Why?
|
Neoplasm Proteins | 4 | 2021 | 3703 | 0.260 |
Why?
|
Sarcoma, Kaposi | 2 | 2019 | 370 | 0.260 |
Why?
|
Central Nervous System Neoplasms | 4 | 2017 | 895 | 0.260 |
Why?
|
Vascular Diseases | 1 | 2013 | 1161 | 0.250 |
Why?
|
Pyrazines | 3 | 2021 | 1230 | 0.250 |
Why?
|
Aged | 62 | 2023 | 163280 | 0.250 |
Why?
|
Survival Rate | 15 | 2021 | 12788 | 0.250 |
Why?
|
Transplants | 1 | 2006 | 209 | 0.230 |
Why?
|
Recombinant Fusion Proteins | 1 | 2012 | 3772 | 0.230 |
Why?
|
Ifosfamide | 4 | 2014 | 228 | 0.230 |
Why?
|
Combined Modality Therapy | 11 | 2019 | 8642 | 0.220 |
Why?
|
Organ Transplantation | 2 | 2010 | 1139 | 0.220 |
Why?
|
Drug Resistance, Neoplasm | 10 | 2019 | 5172 | 0.220 |
Why?
|
Indoles | 2 | 2008 | 1839 | 0.220 |
Why?
|
Young Adult | 25 | 2023 | 56430 | 0.220 |
Why?
|
Survival Analysis | 10 | 2020 | 10252 | 0.210 |
Why?
|
Immunologic Factors | 2 | 2009 | 1580 | 0.210 |
Why?
|
Oxazines | 2 | 2015 | 298 | 0.200 |
Why?
|
Transplantation, Homologous | 7 | 2023 | 4776 | 0.200 |
Why?
|
Methotrexate | 5 | 2014 | 1727 | 0.200 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1333 | 0.200 |
Why?
|
Lymphocytes | 1 | 2009 | 2617 | 0.200 |
Why?
|
Tumor Lysis Syndrome | 1 | 2021 | 42 | 0.190 |
Why?
|
Adenine | 2 | 2024 | 936 | 0.190 |
Why?
|
Histiocytes | 1 | 2021 | 103 | 0.190 |
Why?
|
Clinical Trials as Topic | 6 | 2019 | 7913 | 0.190 |
Why?
|
Carmustine | 3 | 2020 | 137 | 0.190 |
Why?
|
Piperidines | 3 | 2024 | 1602 | 0.190 |
Why?
|
Neoplasm, Residual | 6 | 2023 | 973 | 0.190 |
Why?
|
Disease Management | 3 | 2021 | 2459 | 0.180 |
Why?
|
Retreatment | 2 | 2019 | 610 | 0.180 |
Why?
|
Follow-Up Studies | 16 | 2024 | 39050 | 0.180 |
Why?
|
Endemic Diseases | 1 | 2021 | 182 | 0.180 |
Why?
|
Radiotherapy | 5 | 2016 | 1533 | 0.180 |
Why?
|
Therapies, Investigational | 1 | 2021 | 112 | 0.180 |
Why?
|
Neoplasms | 7 | 2023 | 21683 | 0.180 |
Why?
|
Genes, myc | 1 | 2021 | 399 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 260 | 0.170 |
Why?
|
Music | 1 | 2023 | 263 | 0.170 |
Why?
|
Neutropenia | 2 | 2023 | 895 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 692 | 0.170 |
Why?
|
Drug Administration Schedule | 9 | 2021 | 4933 | 0.170 |
Why?
|
Adolescent | 25 | 2023 | 85781 | 0.170 |
Why?
|
Private Practice | 1 | 2019 | 154 | 0.160 |
Why?
|
Tumor Escape | 1 | 2021 | 349 | 0.160 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 724 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2016 | 193 | 0.160 |
Why?
|
Angiogenesis Inhibitors | 1 | 2008 | 2038 | 0.160 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 12959 | 0.160 |
Why?
|
Neoplasms, Second Primary | 5 | 2017 | 1061 | 0.160 |
Why?
|
Remission Induction | 7 | 2021 | 2386 | 0.150 |
Why?
|
Immunohistochemistry | 7 | 2014 | 11366 | 0.150 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2635 | 0.150 |
Why?
|
Heart | 2 | 2010 | 4467 | 0.150 |
Why?
|
Sulfonamides | 2 | 2021 | 1938 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3507 | 0.150 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1519 | 0.150 |
Why?
|
Time Factors | 8 | 2021 | 40075 | 0.150 |
Why?
|
Aged, 80 and over | 26 | 2018 | 57776 | 0.150 |
Why?
|
Myocardium | 1 | 2010 | 4776 | 0.150 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2018 | 437 | 0.150 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 850 | 0.140 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2018 | 323 | 0.140 |
Why?
|
Drug Eruptions | 1 | 2019 | 297 | 0.140 |
Why?
|
Pyridines | 3 | 2015 | 2825 | 0.140 |
Why?
|
Databases, Factual | 1 | 2012 | 7729 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-rel | 2 | 2007 | 71 | 0.140 |
Why?
|
Pyrimidines | 4 | 2019 | 2942 | 0.140 |
Why?
|
Heart Diseases | 3 | 2023 | 2788 | 0.140 |
Why?
|
Herpesvirus 8, Human | 1 | 2018 | 258 | 0.140 |
Why?
|
Graft vs Host Disease | 3 | 2023 | 2957 | 0.140 |
Why?
|
Boronic Acids | 2 | 2010 | 965 | 0.140 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2017 | 194 | 0.140 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2017 | 227 | 0.140 |
Why?
|
Gene Rearrangement | 2 | 2018 | 1179 | 0.140 |
Why?
|
Benzamides | 1 | 2021 | 1379 | 0.130 |
Why?
|
Age Factors | 5 | 2019 | 18370 | 0.130 |
Why?
|
Retrospective Studies | 25 | 2023 | 77449 | 0.130 |
Why?
|
Cohort Studies | 12 | 2016 | 40561 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
Opportunistic Infections | 1 | 2018 | 389 | 0.130 |
Why?
|
Immunophenotyping | 3 | 2016 | 1880 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2019 | 657 | 0.130 |
Why?
|
Exanthema | 1 | 2019 | 501 | 0.130 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2019 | 2948 | 0.130 |
Why?
|
Enteropathy-Associated T-Cell Lymphoma | 1 | 2014 | 12 | 0.120 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2014 | 35 | 0.120 |
Why?
|
Europe | 1 | 2021 | 3339 | 0.120 |
Why?
|
Mentors | 1 | 2019 | 631 | 0.120 |
Why?
|
Sequence Deletion | 1 | 2018 | 1526 | 0.120 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 627 | 0.120 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1401 | 0.120 |
Why?
|
Prednisolone | 2 | 2018 | 334 | 0.110 |
Why?
|
Central Nervous System | 1 | 2021 | 1357 | 0.110 |
Why?
|
Bone Marrow Examination | 1 | 2013 | 157 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 3 | 2017 | 1352 | 0.110 |
Why?
|
Carotid Artery, Common | 1 | 2013 | 183 | 0.110 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2727 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.110 |
Why?
|
Herpes Zoster | 1 | 2015 | 264 | 0.110 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9438 | 0.100 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 111 | 0.100 |
Why?
|
United States | 10 | 2021 | 69872 | 0.100 |
Why?
|
Viral Load | 3 | 2018 | 3299 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2017 | 1873 | 0.100 |
Why?
|
HIV Infections | 5 | 2018 | 16718 | 0.100 |
Why?
|
Radiation Pneumonitis | 1 | 2011 | 104 | 0.100 |
Why?
|
Hydrocephalus | 1 | 2017 | 748 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1265 | 0.100 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2016 | 648 | 0.090 |
Why?
|
Testicular Neoplasms | 1 | 2017 | 804 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1832 | 0.090 |
Why?
|
Antigens, CD | 1 | 2021 | 4026 | 0.090 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4042 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1897 | 0.090 |
Why?
|
Fever | 1 | 2017 | 1616 | 0.090 |
Why?
|
Headache | 1 | 2017 | 1226 | 0.090 |
Why?
|
Pyrazoles | 1 | 2019 | 1972 | 0.080 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1420 | 0.080 |
Why?
|
Specimen Handling | 1 | 2013 | 694 | 0.080 |
Why?
|
Comorbidity | 5 | 2018 | 10388 | 0.080 |
Why?
|
Child | 10 | 2023 | 77709 | 0.080 |
Why?
|
Hospice Care | 1 | 2015 | 672 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10180 | 0.080 |
Why?
|
Procarbazine | 2 | 2019 | 181 | 0.080 |
Why?
|
Preoperative Care | 1 | 2017 | 2250 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 548 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.080 |
Why?
|
Treatment Failure | 2 | 2012 | 2618 | 0.080 |
Why?
|
Tachycardia | 1 | 2010 | 619 | 0.080 |
Why?
|
Leukemia | 1 | 2016 | 1511 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2017 | 6538 | 0.080 |
Why?
|
Helicobacter pylori | 1 | 2011 | 382 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 492 | 0.080 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4665 | 0.080 |
Why?
|
Medical Errors | 1 | 2016 | 1297 | 0.070 |
Why?
|
Antigens, CD20 | 1 | 2008 | 199 | 0.070 |
Why?
|
TNF Receptor-Associated Factor 1 | 1 | 2007 | 50 | 0.070 |
Why?
|
Magnetic Resonance Angiography | 1 | 2013 | 1442 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2008 | 349 | 0.070 |
Why?
|
Databases as Topic | 1 | 2008 | 475 | 0.070 |
Why?
|
Bone Marrow Cells | 2 | 2013 | 2513 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 934 | 0.070 |
Why?
|
Troponin | 1 | 2010 | 524 | 0.070 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2008 | 241 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1836 | 0.070 |
Why?
|
Aniline Compounds | 1 | 2010 | 986 | 0.070 |
Why?
|
Aorta | 1 | 2013 | 2061 | 0.070 |
Why?
|
Piperazines | 2 | 2016 | 2488 | 0.070 |
Why?
|
Sirolimus | 2 | 2012 | 1564 | 0.060 |
Why?
|
Registries | 2 | 2013 | 8089 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2015 | 2455 | 0.060 |
Why?
|
Oligonucleotides | 1 | 2008 | 572 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7785 | 0.060 |
Why?
|
Lymph Node Excision | 1 | 2011 | 1261 | 0.060 |
Why?
|
Mesna | 1 | 2004 | 66 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4386 | 0.060 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2011 | 868 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2017 | 3523 | 0.060 |
Why?
|
Administration, Oral | 3 | 2019 | 3913 | 0.060 |
Why?
|
Macrophages | 1 | 2018 | 5655 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2915 | 0.060 |
Why?
|
Research Personnel | 1 | 2008 | 573 | 0.060 |
Why?
|
Thiazoles | 1 | 2011 | 1483 | 0.060 |
Why?
|
Lymphocyte Count | 2 | 2018 | 793 | 0.060 |
Why?
|
Thiotepa | 2 | 2014 | 66 | 0.060 |
Why?
|
Sex Distribution | 1 | 2009 | 2297 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2014 | 5974 | 0.060 |
Why?
|
Observer Variation | 1 | 2008 | 2593 | 0.050 |
Why?
|
Leucovorin | 1 | 2004 | 628 | 0.050 |
Why?
|
Busulfan | 2 | 2014 | 263 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2008 | 3701 | 0.050 |
Why?
|
Risk Factors | 9 | 2021 | 72290 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9583 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 9959 | 0.050 |
Why?
|
Hematologic Diseases | 2 | 2019 | 498 | 0.050 |
Why?
|
Population Surveillance | 1 | 2012 | 2616 | 0.050 |
Why?
|
DNA, Viral | 2 | 2018 | 2225 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3749 | 0.050 |
Why?
|
Child, Preschool | 3 | 2018 | 41006 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 15076 | 0.050 |
Why?
|
Cancer Vaccines | 1 | 2008 | 1023 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7279 | 0.050 |
Why?
|
SEER Program | 2 | 2015 | 1508 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 1 | 2008 | 1990 | 0.040 |
Why?
|
Neoplasm Invasiveness | 1 | 2008 | 3616 | 0.040 |
Why?
|
Pneumonia | 1 | 2012 | 2133 | 0.040 |
Why?
|
Mediastinum | 2 | 2012 | 267 | 0.040 |
Why?
|
Morpholines | 2 | 2015 | 571 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2503 | 0.040 |
Why?
|
HIV-1 | 2 | 2017 | 6939 | 0.040 |
Why?
|
Disease Progression | 5 | 2015 | 13284 | 0.040 |
Why?
|
Aminopyridines | 2 | 2015 | 542 | 0.040 |
Why?
|
Data Collection | 1 | 2008 | 3341 | 0.040 |
Why?
|
Mutation | 2 | 2021 | 29786 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2219 | 0.040 |
Why?
|
DNA | 1 | 2013 | 7301 | 0.040 |
Why?
|
Biopsy | 1 | 2011 | 6756 | 0.040 |
Why?
|
Thalidomide | 2 | 2014 | 890 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2010 | 892 | 0.040 |
Why?
|
Pandemics | 3 | 2023 | 8388 | 0.040 |
Why?
|
Podophyllotoxin | 1 | 2017 | 21 | 0.040 |
Why?
|
Anxiety | 2 | 2023 | 4297 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2007 | 2969 | 0.040 |
Why?
|
Prospective Studies | 6 | 2020 | 53288 | 0.040 |
Why?
|
Stress, Psychological | 2 | 2023 | 4245 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 3508 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2018 | 387 | 0.040 |
Why?
|
Phosphorylation | 1 | 2008 | 8436 | 0.040 |
Why?
|
Games, Experimental | 1 | 2016 | 32 | 0.040 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2019 | 659 | 0.030 |
Why?
|
Anemia | 2 | 2018 | 1506 | 0.030 |
Why?
|
NF-kappa B | 1 | 2005 | 2499 | 0.030 |
Why?
|
Fatigue | 2 | 2014 | 1531 | 0.030 |
Why?
|
Curriculum | 2 | 2022 | 3605 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
Immunotherapy | 3 | 2023 | 4445 | 0.030 |
Why?
|
Melphalan | 1 | 2017 | 431 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4149 | 0.030 |
Why?
|
Radiotherapy Dosage | 2 | 2012 | 2879 | 0.030 |
Why?
|
Dioxygenases | 1 | 2017 | 316 | 0.030 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 1995 | 293 | 0.030 |
Why?
|
Apoptosis | 2 | 2008 | 9727 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 367 | 0.030 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 98 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 222 | 0.030 |
Why?
|
Drug Therapy | 1 | 2017 | 497 | 0.030 |
Why?
|
Radioimmunotherapy | 1 | 2014 | 91 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 2682 | 0.030 |
Why?
|
Herpesvirus 3, Human | 1 | 2015 | 204 | 0.030 |
Why?
|
Drug Interactions | 1 | 2018 | 1460 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
Patient Selection | 2 | 2018 | 4215 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2008 | 19905 | 0.030 |
Why?
|
Boston | 2 | 2021 | 9313 | 0.030 |
Why?
|
Chemokines | 1 | 2017 | 970 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1692 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 240 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 847 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 866 | 0.030 |
Why?
|
Phagocytosis | 1 | 2018 | 1539 | 0.030 |
Why?
|
Lung | 1 | 2011 | 9856 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2017 | 732 | 0.030 |
Why?
|
Hepatitis B Antibodies | 1 | 2013 | 159 | 0.030 |
Why?
|
Receptors, HIV | 1 | 2013 | 162 | 0.030 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 379 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1770 | 0.030 |
Why?
|
Lymphopenia | 1 | 2014 | 285 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1677 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 315 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2013 | 305 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2021 | 5078 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1878 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
Nausea | 1 | 2014 | 673 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1999 | 2765 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3586 | 0.020 |
Why?
|
Signal Transduction | 2 | 2019 | 23403 | 0.020 |
Why?
|
Gonads | 1 | 2011 | 109 | 0.020 |
Why?
|
Dosage Forms | 1 | 2010 | 56 | 0.020 |
Why?
|
Virus Activation | 1 | 2013 | 319 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2012 | 258 | 0.020 |
Why?
|
HIV | 1 | 2018 | 1604 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2017 | 820 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3670 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2013 | 497 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5007 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2011 | 647 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12245 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13408 | 0.020 |
Why?
|
Filgrastim | 1 | 2009 | 133 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2291 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2274 | 0.020 |
Why?
|
Hepatitis B virus | 1 | 2013 | 513 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2012 | 322 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12026 | 0.020 |
Why?
|
Virus Replication | 1 | 2017 | 2534 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2005 | 8428 | 0.020 |
Why?
|
Educational Measurement | 1 | 2016 | 1210 | 0.020 |
Why?
|
Massachusetts | 2 | 2014 | 8663 | 0.020 |
Why?
|
RNA, Viral | 1 | 2017 | 2902 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2012 | 538 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8324 | 0.020 |
Why?
|
Carboplatin | 1 | 2011 | 801 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1094 | 0.020 |
Why?
|
Teaching | 1 | 2016 | 1174 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2649 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4186 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4479 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 226 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2012 | 1801 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 537 | 0.020 |
Why?
|
Hepatitis B | 1 | 2013 | 695 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2017 | 2072 | 0.020 |
Why?
|
Incidence | 3 | 2015 | 20947 | 0.020 |
Why?
|
Medicare | 2 | 2015 | 6566 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1316 | 0.020 |
Why?
|
Leukocytes | 1 | 1995 | 2043 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2011 | 826 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 8949 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 1876 | 0.020 |
Why?
|
Social Class | 1 | 2015 | 1999 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1581 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3743 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3610 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2017 | 5524 | 0.020 |
Why?
|
Heterozygote | 1 | 2013 | 2804 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1799 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1405 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2017 | 3023 | 0.020 |
Why?
|
Transplantation Chimera | 1 | 2008 | 612 | 0.020 |
Why?
|
Gene Deletion | 1 | 2013 | 2751 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 1530 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4554 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 2988 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1622 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
Age of Onset | 1 | 2010 | 3271 | 0.010 |
Why?
|
Thrombosis | 1 | 2017 | 2968 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 35421 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2942 | 0.010 |
Why?
|
Palliative Care | 1 | 2018 | 3493 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1364 | 0.010 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1715 | 0.010 |
Why?
|
Medical Records | 1 | 2008 | 1413 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3158 | 0.010 |
Why?
|
Lung Transplantation | 1 | 2011 | 1153 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9849 | 0.010 |
Why?
|
Neutrophils | 1 | 1995 | 3719 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2018 | 4256 | 0.010 |
Why?
|
Hepatitis C | 1 | 2013 | 1591 | 0.010 |
Why?
|
Diarrhea | 1 | 2009 | 1348 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10397 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 5987 | 0.010 |
Why?
|
Blood Platelets | 1 | 2010 | 2508 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6622 | 0.010 |
Why?
|
Heart Failure | 1 | 2023 | 10900 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 9648 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2015 | 13989 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 12720 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16365 | 0.010 |
Why?
|
Karyotyping | 1 | 1999 | 1243 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 15295 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9146 | 0.010 |
Why?
|
Inflammation | 1 | 1995 | 10638 | 0.010 |
Why?
|
Risk Assessment | 2 | 2011 | 23338 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15540 | 0.010 |
Why?
|
Algorithms | 1 | 2015 | 13881 | 0.010 |
Why?
|
Peritonitis | 1 | 1995 | 365 | 0.010 |
Why?
|
P-Selectin | 1 | 1995 | 600 | 0.010 |
Why?
|
Mice | 2 | 2016 | 81183 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14722 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 15226 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1995 | 1588 | 0.010 |
Why?
|
Hypertension | 1 | 2009 | 8480 | 0.010 |
Why?
|
Cell Adhesion | 1 | 1995 | 3144 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 16689 | 0.010 |
Why?
|
Animals | 2 | 2016 | 168757 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 17446 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1995 | 4456 | 0.000 |
Why?
|
Mice, Knockout | 1 | 1995 | 14557 | 0.000 |
Why?
|